Q413299: Difference between revisions
Added [ks] description: کیٖمیٲیی مُرَکَب, batch #96070 |
Removed claim: DrugBank ID (P715): 00112, batch #233443 |
||||||||||||||
(39 intermediate revisions by 14 users not shown) | |||||||||||||||
label / zh-hans | label / zh-hans | ||||||||||||||
贝伐珠单抗 | |||||||||||||||
label / zh-hant | label / zh-hant | ||||||||||||||
貝伐珠單抗 | |||||||||||||||
label / zh-hk | label / zh-hk | ||||||||||||||
label / zh-cn | label / zh-cn | ||||||||||||||
贝伐珠单抗 | |||||||||||||||
label / zh-sg | label / zh-sg | ||||||||||||||
label / zh-tw | label / zh-tw | ||||||||||||||
label / ru | label / ru | ||||||||||||||
бевацизумаб | |||||||||||||||
label / tr | label / tr | ||||||||||||||
Bevasizumab | |||||||||||||||
label / sl | label / sl | ||||||||||||||
bevacizumab | |||||||||||||||
label / hr | label / hr | ||||||||||||||
bevacizumab | |||||||||||||||
label / nb | label / nb | ||||||||||||||
bevacizumab | |||||||||||||||
aliases / zh / 0 | aliases / zh / 0 | ||||||||||||||
安维汀® | |||||||||||||||
aliases / zh / 1 | aliases / zh / 1 | ||||||||||||||
癌思停® | |||||||||||||||
aliases / zh / 2 | aliases / zh / 2 | ||||||||||||||
达攸同® | |||||||||||||||
aliases / zh / 3 | aliases / zh / 3 | ||||||||||||||
aliases / zh / 4 | aliases / zh / 4 | ||||||||||||||
aliases / zh / 5 | aliases / zh / 5 | ||||||||||||||
aliases / ja / 0 | aliases / ja / 0 | ||||||||||||||
ベヴァシズマブ | |||||||||||||||
aliases / hr / 0 | aliases / hr / 0 | ||||||||||||||
avastin | |||||||||||||||
aliases / hr / 1 | aliases / hr / 1 | ||||||||||||||
description / tr | description / tr | ||||||||||||||
farmasötik ilaç | |||||||||||||||
description / ko | description / ko | ||||||||||||||
수많은 유형의 암과 특정 눈병을 치료하기 위해 사용되는 약물 | |||||||||||||||
description / zh | description / zh | ||||||||||||||
药物 | |||||||||||||||
Property / instance of | |||||||||||||||
Property / instance of: medication / rank | |||||||||||||||
Property / instance of: medication / reference | |||||||||||||||
DrugBank ID: 00112 language of work or name: English title: Bevacizumab (English) publication date: 17 November 2015
| |||||||||||||||
Property / instance of | |||||||||||||||
Property / instance of: chemical compound / rank | |||||||||||||||
Property / instance of: chemical compound / reference | |||||||||||||||
DrugBank ID: 00112 language of work or name: English title: Bevacizumab (English) publication date: 17 November 2015
| |||||||||||||||
Property / instance of | |||||||||||||||
Property / instance of: biopharmaceutical / rank | |||||||||||||||
Property / instance of: biopharmaceutical / reference | |||||||||||||||
DrugBank ID: 00112 language of work or name: English title: Bevacizumab (English) publication date: 17 November 2015
| |||||||||||||||
Property / instance of | |||||||||||||||
Property / instance of: monoclonal antibody / rank | |||||||||||||||
Property / instance of: monoclonal antibody / reference | |||||||||||||||
DrugBank ID: 00112 language of work or name: English title: Bevacizumab (English) publication date: 17 November 2015
| |||||||||||||||
Property / instance of | |||||||||||||||
Property / instance of: essential medicine / rank | |||||||||||||||
Property / instance of | |||||||||||||||
Property / instance of: female reproductive toxicant / rank | |||||||||||||||
Property / instance of: female reproductive toxicant / reference | |||||||||||||||
retrieved: 19 February 2020
reference URL: https://oehha.ca.gov/chemicals/bevacizumab | |||||||||||||||
Property / instance of | |||||||||||||||
Property / instance of: developmental toxicant / rank | |||||||||||||||
Property / instance of: developmental toxicant / qualifier | |||||||||||||||
Property / instance of: developmental toxicant / reference | |||||||||||||||
retrieved: 25 February 2020
reference URL: https://oehha.ca.gov/chemicals/bevacizumab | |||||||||||||||
Property / DrugBank ID | |||||||||||||||
Property / DrugBank ID: 00112 / rank | |||||||||||||||
Property / DrugBank ID: 00112 / reference | |||||||||||||||
DrugBank ID: 00112 language of work or name: English title: Bevacizumab (English) publication date: 17 November 2015
| |||||||||||||||
Property / DrugBank ID: 00112 / reference | |||||||||||||||
retrieved: April 2018
| |||||||||||||||
Property / Encyclopædia Britannica Online ID: topic/bevacizumab / qualifier | |||||||||||||||
subject named as: bevacizumab | |||||||||||||||
Property / instance of | |||||||||||||||
Property / instance of: type of chemical entity / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / DrugBank ID | |||||||||||||||
Property / DrugBank ID: DB00112 / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / subject has role | |||||||||||||||
Property / subject has role: monoclonal antibody / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / subject has role: monoclonal antibody / reference | |||||||||||||||
stated in: DrugBank DrugBank ID: 00112 language of work or name: English title: Bevacizumab (English) publication date: 17 November 2015
| |||||||||||||||
Property / subject has role | |||||||||||||||
Property / subject has role: female reproductive toxicant / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / subject has role: female reproductive toxicant / reference | |||||||||||||||
stated in: California Proposition 65 list of chemicals retrieved: 19 February 2020
reference URL: https://oehha.ca.gov/chemicals/bevacizumab | |||||||||||||||
Property / subject has role | |||||||||||||||
Property / subject has role: developmental toxicant / rank | |||||||||||||||
Deprecated rank | |||||||||||||||
Property / subject has role: developmental toxicant / qualifier | |||||||||||||||
Property / subject has role: developmental toxicant / reference | |||||||||||||||
stated in: California Proposition 65 list of chemicals retrieved: 25 February 2020
reference URL: https://oehha.ca.gov/chemicals/bevacizumab | |||||||||||||||
Property / subject has role | |||||||||||||||
Property / subject has role: essential medicine / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / medical condition treated | |||||||||||||||
Property / medical condition treated: low-grade serous carcinoma / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / medical condition treated: low-grade serous carcinoma / reference | |||||||||||||||
Property / WikiProjectMed ID | |||||||||||||||
Property / WikiProjectMed ID: Bevacizumab / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / has use | |||||||||||||||
Property / has use: medication / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / has use: medication / reference | |||||||||||||||
stated in: DrugBank DrugBank ID: 00112 language of work or name: English title: Bevacizumab (English) publication date: 17 November 2015
| |||||||||||||||
Property / has use | |||||||||||||||
Property / has use: biopharmaceutical / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / has use: biopharmaceutical / reference | |||||||||||||||
stated in: DrugBank DrugBank ID: 00112 language of work or name: English title: Bevacizumab (English) publication date: 17 November 2015
| |||||||||||||||
Property / UMLS CUI | |||||||||||||||
Property / UMLS CUI: C0796392 / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / UMLS CUI: C0796392 / reference | |||||||||||||||
Property / subclass of | |||||||||||||||
Property / subclass of: chemical compound / rank | |||||||||||||||
Normal rank | |||||||||||||||
links / trwiki / name | links / trwiki / name | ||||||||||||||